共 1400 条
[1]
Charcot J-M(1869)Deux cas d’atrophie musculaire progressive avec lésions de la substance grise et des faiseaux antéro-latéraux de la moelle épinière Arch Physiol Norm Pathol. 2 744-760
[2]
Joffroy A(2001)The course of the terminal phase in patients with amyotrophic lateral sclerosis J Neurol 248 612-6
[3]
Neudert C(2003)Prognosis in amyotrophic lateral sclerosis: a population-based study Neurology 60 813-9
[4]
Oliver D(1994)A controlled trial of riluzole in amyotrophic lateral sclerosis N Engl J Med 330 585-91
[5]
Wasner M(1996)Dose-ranging study of riluzole in amyotrophic lateral sclerosis Lancet 347 1425-31
[6]
Borasio GD(2017)Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis Degener Neurol Neuromuscul Dis 7 61-70
[7]
del Aguila MA(2017)Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial Lancet Neurol 16 505-12
[8]
Longstreth WT(2016)A long-term safety and efficacy extension study of patients diagnosed with amyotrophic lateral sclerosis (ALS) and treated with edaravone (MCI-186) Neurology 86 Suppl. P3.192-30
[9]
McGuire V(2020)Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis N Engl J Med 383 919-9
[10]
Koepsell TD(2020)Long-term treatment with AMX0035 in the open-label extension of CENTAUR, a randomized controlled trial in individuals with amyotrophic lateral sclerosis Muscle Nerve 62 105-72